List view / Grid view
16 December 2010 | By Dana Buckman, Senior Scientist, Biomarkers – Translational Research, Pfizer
Flow cytometry can be used to advance our understanding of diseases in multiple ways. Drug effects and dosages can be ascertained in vitro, along with patient selection based on mutations and antigen profiles. Within the Diagnostic Biomarkers group of Translational Research at Pfizer, we are utilising flow cytometry in conjunction…
18 November 2010 | By BUSINESS WIRE
Companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients...
9 November 2010 | By NG Online News
Senior executives from Eli Lilly, AstraZeneca, Johnson and Johnson & Pfizer to discuss the ROI for "non-surrogate" biomarkers, dose selection biomarkers and biomarkers of efficacy.
8 November 2010 | By ISPE
ISPE, announced that Genentech’s ECP-1 Bacterial Manufacturing Facility is the overall winner...
18 October 2010 | By Emma Naylor, NG Online News
Pharmaceutical heads met last week as a result of a drugs recall after an ingrediant mix up in breast cancer pill Anastrozole.
10 September 2010 | By NG Online News
Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?
5 August 2010 | By Generex Biotechnology Corporation
Generex announced that it has named Craig Eagle, M.D. to its scientific advisory board...
21 July 2010 | By NG Online News
Back in May, it was announced that new stem cell research would reduce the need for animal testing...
2 July 2010 | By NG Online News
The pharmaceutical industry has faced well documented challenges over the last 12 months, such as the Pfizer...
12 December 2009 | By
The use of RNAi screening to identify potential drug targets has enjoyed great success in recent years as a robust method for linking genes to a disease process through a functional assessment of a gene in an experimental model1. True, RNAi screening is complicated by problems such as off-target effects…
9 October 2009 | By
Pharmacodynamic biomarkers in drug discovery: Developing a new drug is an expensive and time-consuming business1-3. A substantial part of the overall cost of drug development is the investment in molecules that fails at some point during the development process and it is necessary to identify these compounds as early as possible.…
23 November 2007 | By
A round table discussion covering the driving forces behind the integration of automated technology within the pharmaceutical industry, the procedures that are followed when implementing new automated techniques, current areas of drug discovery most benefiting from lab automation, how lab automation advanced the drug discovery marketplace over the last five…
25 January 2007 | By Peter Haddock, PhD., Pfizer Global Research and Development, CNS Pharmacology
Ion channels play key roles in regulating cardiac, neuronal and secretory tissue function. As such, the pharmacological modulation of ion channel activities may provide an effective means to positively impact upon an array of disease states. However, the reliance on low-capacity manually operated electrophysiology screening systems has dictated that ion…
